VitaNova Life Sciences (VNOV) Accumulated Expenses (2017 - 2026)

VitaNova Life Sciences' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $81951.0 for Q1 2026.

• Quarterly Accumulated Expenses changed N/A year-over-year to $81951.0 in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $81951.0 (changed N/A YoY) and the FY2025 annual result came in at $60885.0, changed N/A from the prior year.
• Accumulated Expenses was $81951.0 for Q1 2026 at VitaNova Life Sciences, up from $68713.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $81951.0 in Q1 2026 and bottomed at $38391.0 in Q1 2022.
• A 5-year average of $54362.5 and a median of $50672.5 in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 61.02% — and 2023, when it fell 4.94%.
• VitaNova Life Sciences' Accumulated Expenses stood at $53343.0 in 2022, then declined by 4.94% to $50707.0 in 2023, then declined by 1.0% to $50202.0 in 2024, then surged by 36.87% to $68713.0 in 2025, then advanced by 19.27% to $81951.0 in 2026.
• Business Quant data shows VNOV's Accumulated Expenses at $81951.0 in Q1 2026, $68713.0 in Q4 2025, and $60885.0 in Q2 2025.